Im guessing Mylan wanted the whole pie but DB said no. For me, that reaffirms his commitment to bringing a truly disruptive and different toxin to market while continuing to expand in new indications. I also believe DB will do everything in his power to get RT002 to market as quickly as possible.
In my speculation, denying a Mylan takeover shows DB has a vision to grow Revance into a neuromodulator behemoth. I can't imagine his visions stops with just toxins.
Market Data 
Markets 
AI
